Crossmark

Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model

Crossref DOI link: https://doi.org/10.1186/s12955-020-01481-2

Published Online: 2020-07-20

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Franken, Mira D. https://orcid.org/0000-0003-2285-7411
de Hond, Anne

Degeling, Koen

Punt, Cornelis J. A.

Koopman, Miriam

Uyl-de Groot, Carin A.

Versteegh, Matthijs M.

van Oijen, Martijn G. H.
License Information

Text and Data Mining valid from 2020-07-20

Version of Record valid from 2020-07-20
More Information

Article History

Received: 5 March 2020

Accepted: 7 July 2020

First Online: 20 July 2020

Ethics approval and consent to participate

: Previously collected quality of life questionnaires in the phase III randomized clinical trial, CAIRO3 study (NCT00442637) were used for this study. Informed consent was given by all patients prior to inclusion in the CAIRO3 study. Results of the CAIRO3 study have been reported elsewhere [].

: Not applicable for this section.

: Mira D. Franken declares no competing interests; Anne de Hond declares no competing interests; Koen Degeling declares no competing interests; Cornelis J.A. Punt is a principal investigator of the CAIRO3 study, a randomized controlled-trial sponsored by the Dutch Colorectal Cancer Group (DCCG); Miriam Koopman is a principal investigator of the CAIRO3 study; Carin A. Uyl–de Groot has received unrestricted research grants from Boehringer Ingelheim, Astellas, Celgene, Sanofi, Janssen-Cilag, Bayer, Amgen, Genzyme, Merck, Glycostem Therapeutics, Astra Zeneca, Roche; Matthijs M. Versteegh is a member of the EuroQoL research foundation which develops EQ-5D; Martijn G.H. van Oijen has received unrestricted research funding from Amgen, Lilly, Merck, Nordic and Roche.

Document is current

Any future updates will be listed below